RxDoctor Payments Data

Hector Tamez Aguilar

Interventional Cardiology · Boston, MANPI 1609048909

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (35.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 25.4% of the total. Among interventional cardiology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$123,074in general payments, 2019–2025

Across 271 payments — averaging $454.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$31K
  • Shockwave Medical, Inc$30K
  • Abiomed$17K
  • Medtronic$17K
  • Boston Scientific$16K
  • Biotronik Inc.$5K
  • plus $6K from 8 others
$56,154in research payments, 2019–2025

Across 2 payments — averaging $28,077 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shockwave Medical, Inc$56K

What the payments were for

  • Consulting fees$40,52533%
  • Speaking & faculty fees$43,90036%
  • Travel & lodging$25,80221%
  • Food & beverage$12,84710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,074 in reported general payments places this provider in the 90th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$159,607
Medicare patients
506
Services billed
1,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$32,358
Repatha SureclickEvolocumab20$12,885
Praluent PenAlirocumab13$6,931
Metoprolol Succinate66$979
Atorvastatin Calcium80$944
Carvedilol33$587
ClopidogrelClopidogrel Bisulfate27$547
Losartan Potassium24$385
Lisinopril17$167
Pravastatin Sodium13$157
Isosorbide Mononitrate ErIsosorbide Mononitrate14$151
Furosemide13$94
Amlodipine Besylate18$58
Hydrochlorothiazide15$32
Rosuvastatin Calcium13$23

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →